Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis

British Journal of Pharmacology

Volumn 134, Issue 6, 2001, Pages 1245-1252

  Tsai, T H ^a,b   Lee, C H ^b   Yeh, P H ^b  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Camptothecin; Cyclosporin A; Hepatobiliary excretion; Microdialysis; P glycoprotein; Pharmacokinetics

Indexed keywords

AURANTIIN; BERBERINE; CAMPTOTHECIN; CYCLOSPORIN A; GLYCOPROTEIN P; NARINGENIN; QUERCETIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TRANSPORT; HEPATOBILIARY SYSTEM; MICRODIALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT;

EID: 0035196221     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704363     Document Type: Article

References (53)

1. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors
2. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates
3. Plasma and cerebrospinal fluid pharmacokinetics of 9-amino-camptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates
4. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein
5. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes
6. P-glycoprotein (Pgp) does not affect the cytotoxicity of flavonoids from Sophora flavescens, which also have no effects on Pgp action
7. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
8. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
9. Topoisomerase-targeting antitumor drugs
10. The cell cycle effects of camptothecin
11. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier
12. The P-glycoprotein multidrug transporter
13. MDR2 P-glycoprotein-mediated lipid sectetion and its relevance to biliary drug transport
14. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
15. Non-compartmental analysis
16. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
17. Liquid chromatographic determination of tacrine and its metabolites in rat bile microdialysates
18. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
19. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
20. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
21. Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells
22. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models
23. Mechanism of action of camptothecin
24. Effect of bioflavonoids on vincristine transport across blood-brain barrier
25. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer
26. Camptothecin and its analogs. An overview of their potential in cancer therapeutics
27. Camptothecins: A review of their development and schedules of administration
28. CNS drug design based on principles of blood-brain barrier transport
29. Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver
30. Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression
31. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives
32. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo
33. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier
34. Disruption of the mouse mdr 1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
35. Camptothecin
36. In vivo microdialysis sampling in the bile, blood, and liver of rats to study the disposition of phenol
37. Camptothecin
38. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins
39. Functional involvement of P-glycoprotein in bloodbrain barrier
40. Intravenous microdialysis sampling in awake, freely-moving rats
41. Measurement of unbound caffeic acid in rat blood by on-line microdialysis coupled with liquid chromatography and its application to pharmacokinetic studies
42. Pharmacokinetic and brain distribution of magnolol in the rats after intravenous bolus injection
43. Pharmacokinetic and biliary excretion study of esculetin by microdialysis in rat
44. Biliary excretion of chloramphenicol and chloramphenicol glucuronide in rat by microdialysis
45. Determination of unbound 20(S)-camptothecin in rat bile by online microdialysis coupled to microbore liquid chromatography with fluorescence detection
46. Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection
47. Enterohepatic circulation of chloramphenicol and chloramphenicol glucuronide in rat
48. Restricted transport of cyclosporin A across the bloodbrain barrier by a multidrug transporter P-glycoprotein
49. Camptothecin and taxol: Discovery to clinic
50. Camptothecin. Discovery to clinic
51. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata
52. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain